Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13708172 | 0.89 | BRAF (0.59) | BRAFEGFRCSF1RRAF1LYN | |
| SCHEMBL13711530 | 0.87 | CSF1R (0.47) | BRAFEGFRCSF1RRAF1LYN | |
| SCHEMBL13711496 | 0.84 | PIKFYVE (0.43) | BRAFEGFRCSF1RHPGDSDDR1 | |
| SCHEMBL13711539 | 0.82 | BRAF (0.63) | BRAFEGFRCSF1RABL1 | |
| SCHEMBL13711477 | 0.80 | BRAF (0.46) | BRAFEGFRCSF1RRAF1ABL1 | |
| SCHEMBL13708173 | 0.79 | BRAF (0.76) | BRAFEGFRCSF1RABL1 | |
| SCHEMBL13711533 | 0.78 | BRAF (0.47) | BRAFEGFRRAF1LYNMAP3K7 | |
| SCHEMBL13711479 | 0.77 | ATM (0.57) | BRAFEGFRRAF1LYNMAP3K7 | |
| SCHEMBL13708168 | 0.76 | CSF1R (0.61) | BRAFEGFRCSF1RRAF1LYN | |
| SCHEMBL14097786 | 0.76 | LYN (0.46) | BRAFCSF1RRAF1LYNMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589101-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-09-15 | — | — | US | disclosed |
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287432-A1 | Compounds and Compositions as Protein Kinase Inhibitors | AURKC, PTK2B, FRK | BRAF 102/4885EGFR 98/4885CSF1R 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.